Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease

Abstract

Treatment with this Mab is well tolerated with acceptable immediate adverse reactions. Candida infections are a problem, possibly due to immunosuppression. A significant proportion of patients showed improvement of GvHD, and 63% survive 1 year later. We have not as yet observed the occurrence of malignant lymphomas.